Search Orphan Drug Designations and Approvals
-
Generic Name: | (S)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin- 3-yl)methoxy)benzaldehyde |
---|---|
Date Designated: | 05/16/2022 |
Orphan Designation: | Treatment of Sickle Cell Disease |
Orphan Designation Status: | Designated |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
Global Blood Therapeutics, Inc. 181 Oyster Point Blvd South San Francisco, California 94080 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-